Vertex Pharmaceuticals (Canada) Incorporated

Meetings over time

• Jun 20257 meetingsMarie-Françoise Mégie, Suze Youance, Mohamed-Iqbal Ravalia, Sharon Burey
  Jun 2025: 7 meetings, with Marie-Françoise Mégie, Suze Youance, Mohamed-Iqbal Ravalia, Sharon Burey
• Jul 20250 meetings
  Jul 2025: 0 meetings
• Aug 20250 meetings
  Aug 2025: 0 meetings
• Sep 20250 meetings
  Sep 2025: 0 meetings
• Oct 20250 meetings
  Oct 2025: 0 meetings
• Nov 20252 meetingsMichael Coteau
  Nov 2025: 2 meetings, with Michael Coteau
• Dec 20250 meetings
  Dec 2025: 0 meetings
• Jan 20260 meetings
  Jan 2026: 0 meetings
• Feb 20260 meetings
  Feb 2026: 0 meetings
• Mar 202613 meetingsTony Ince, Tom Kmiec, Parm Bains, Alexander MacKenzie, Justine Frame
  Mar 2026: 13 meetings, with Tony Ince, Tom Kmiec, Parm Bains, Alexander MacKenzie, Justine Frame
• Apr 20260 meetings
  Apr 2026: 0 meetings
• May 20260 meetings
  May 2026: 0 meetings
• Jun 20262 meetingsJuanita Nathan, Braveenan Pradeep
  Jun 2026: 2 meetings, with Juanita Nathan, Braveenan Pradeep
• Jul 20261 meetingKelly DeRidder
  Jul 2026: 1 meeting, with Kelly DeRidder

Hover or focus a month to see who was met.

What they lobby about

• Health25
• Budget24
• Economic Development19
• Federal-Provincial Relations12
• Industry12
• Intellectual Property8
• Research and Development7
• Science and Technology7

The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.

Bills they lobbied on

• S-201National Framework on Sickle Cell Disease Act2

  Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i).

  • Juanita NathanLiberal
  • Kelly DeRidderConservative

  • Braveenan Pradeep · Legislative Assistant · House of Commons

Who they met

House of Commons (16) · Senate of Canada (11) · Health Canada (HC) (2)

In their own words

• Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy
• Engagement with officials on Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
• Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.